Exagen Inc. XGN
Medical Specialities · IPO 2019 · data as of November 13, 2026
Exagen Inc. (XGN) is a healthcare company listed in the US with a market value of about $105M. In the twelve months to September 30, 2026 it had revenue of $72M and net income of -$18M, a net margin of -25.1%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 10% a year, a 5-year average ROIC of -33%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 97% below the current price.
About Exagen
Exagen is listed in the US and classified in medical specialities, IPO year 2019. Revenue went from $32M in 2018 to $67M in 2025, growth of about 10.8% a year. It was profitable in 0 of the last 8 years in our data. Its share count rose by 26% over three years (dilution for shareholders). It spends 9% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72M | $67M | $56M | $53M | $46M | $48M | $42M | $40M | $32M |
| Net income | -$18M | -$20M | -$15M | -$24M | -$47M | -$27M | -$17M | -$12M | -$8M |
| Free cash flow | -$13M | -$14M | -$14M | -$15M | -$36M | -$23M | -$15M | -$10M | -$10M |
| EPS (diluted) | $-0.75 | $-0.93 | $-0.83 | $-1.34 | $-2.77 | $-1.68 | $-1.32 | $-8.46 | $-293.34 |
| Net margin | -25.1% | -30.0% | -27.2% | -45.1% | -104.0% | -55.6% | -39.8% | -29.8% | -24.7% |
| ROIC | — | -26.5% | -33.1% | -39.3% | -47.3% | -16.9% | -17.5% | -9.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Exagen stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 97% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Exagen pay a dividend?
Not currently.
Is Exagen a good stock to buy?
We do not give buy or sell advice. Exagen scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.